Publication date: Dec 20, 2024
The increasing survival rates of oncology patients have led to a corresponding increase in long-time survivors living with chronic cancer-related pain. Data is scarce on the care situation for this distinct clinical entity and on specific therapy requirements, such as interdisciplinary, multimodal pain therapy (IMPT). Our cross-sectional study aimed to assess the current care situation, distinct chronification factors, and optimization potential. This survey addresses this need in Germany, but also provides results with international implications. Via an online survey, German Pain Society members involved in the treatment of long-time survivors with chronic cancer-related pain assessed the current care situation, chronification factors, specific treatment needs, and the required practitioner’s expertise. The German Pain Society’s Cancer Pain Working Group created the non-validated questionnaire using the Delphi method. One hundred fifty-nine Pain Society members across 70% of Germany’s postal regions answered our survey. Respondents (primarily physicians, and 75% with + 6 years of experience) assessed the care situation as worse for chronic cancer-related pain compared to acute pain. Only 10% of the sites provided specific therapy for chronic cancer-related pain (mostly via outpatient treatment). Compared to non-cancer-related pain, additional, cancer-specific chronification factors were assumed, especially at psychological levels, and these need incorporating into therapies. A majority of practitioners recommended cancer-specific IMPT and specific pain expertise for this distinct clinical entity. Members from the German Pain Society assume that there are relevant deficits in the care of long-term survivors with chronic cancer-related pain. The situation may be assessed differently by other groups, e. g., oncologists, and the data relates to Germany. Nevertheless, considering the raising survival rates, it can be supposed that there is reason to be concerned about an increasing care deficit. Thus, besides expanding the range of available treatment and raising awareness, IMPT with specially trained personnel should be developed to address the care needs of cancer survivors experiencing chronic cancer-related pain.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Cancer |
| disease | IDO | entity |
| disease | MESH | Weaning |
| disease | MESH | complications |
| disease | MESH | causes |
| disease | MESH | recurrence |
| drug | DRUGBANK | Trestolone |
| disease | MESH | chronic pain |
| disease | IDO | country |
| disease | IDO | process |
| pathway | REACTOME | Translation |
| disease | MESH | anxiety |
| disease | MESH | syndromes |
| disease | IDO | facility |
| disease | MESH | death |
| disease | MESH | Depression |
| disease | MESH | polyneuropathy |
| disease | MESH | neuropathic pain |
| disease | MESH | COVID19 |
| pathway | REACTOME | Reproduction |
| disease | MESH | musculoskeletal pain |
| disease | IDO | symptom |
| disease | MESH | low back pain |
| drug | DRUGBANK | Diethylstilbestrol |
| disease | MESH | chronic post surgical pain |
| drug | DRUGBANK | Ranitidine |
| drug | DRUGBANK | Sulpiride |